 REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 GLOBE NEWSWIRE -- Ayala Pharmaceuticals, Inc. NASDAQ: AYLA, a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that interim results from the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrentmetastatic RM adenoid cystic carcinoma ACC harbouring Notch activating mutations will be presented in an oral presentation at the European Society for Medical Oncology ESMO Virtual Congress 2020, being held September 19-September 21, 2020. Oral presentation information is as follows:Title: ACCURACY a Phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrentmetastatic RM adenoid cystic carcinoma ACC harboring Notch activating mutations Notchmut Session Title: Mini Oral Presentation Session Date and Time: September 18, 2020, 03:55 CEST Presentation Number: 919MO Presenter: Renata Ferrarotto, MD, MD Anderson Cancer CenterThe presentation will be available to registrants of the ESMO Virtual Congress 2020 at 03:55 CEST on September 18, 2020. The presentation will be archived under Events and Presentations in the Investors section of Ayalas website at ir.ayalapharma.com. About Ayala Pharmaceuticals Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer TNBC, T-cell Acute Lymphoblastic Leukemia T-ALL, Desmoid Tumors and Multiple Myeloma MM in collaboration with Novartis. Ayalas lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC ACCURACY bearing Notch activating mutations. For more information, visit Julie Seidel Stern Investor Relations, Inc. 212-362-1200 Pharmaceuticals: 1-857-444-0553 